Immunos Therapeutics has picked up Pfizer Ventures as an investor as it looks to move its lead immuno-oncology drug candidate into clinical testing.
Switzerland-based immunotherapy developer Immunos Therapeutics has completed a CHF15m ($15.3m) series A round co-led by Pfizer Ventures, the corporate venturing arm of pharmaceutical firm Pfizer.
Life sciences-focused venture capital firm BioMedPartners co-led the round, which included VC firm Redalpine, multi-family office Wille Finance, investment firms Schroder Adveq and Bernina BioInvest, and undisclosed private and existing investors.
Founded in 2014 as a spinout of University of Zurich and University of Basel, Immunos Therapeutics is working on immunotherapy-driven treatments for cancer and autoimmune diseases.
The funding will go toward advancing its technology and will support the first clinical trials for its lead candidate, iosH2, and further preclinical assets centred around its target indications.
Pfizer Ventures principal Michael Baran has joined the board of directors together with Markus Hosang of BioMedPartners, Reinhard Ambros, who used to be CEO of pharmaceutical firm Novartis’ Novartis Venture Fund unit, and former Novartis CEO Daniel Vasella.
